When leadership changes at the FDA, as with Vinay Prasad succeeding Peter Marks, a core tension emerges. The new head isn't obligated to follow prior agreements, but abruptly shifting regulatory expectations for companies mid-development creates industry whiplash and erodes trust in the agency's consistency.

The drama surrounding Sarepta's gene therapy, where a top regulator was ousted after political pushback and later reinstated, shows the FDA is now more amenable to outside influence. This case study indicates that presidential and activist pressure can directly impact regulatory enforcement and personnel decisions, moving beyond purely scientific considerations.

CellSci's drug trial ran into a stricter FDA under one administration after a period of more lenient approvals under the previous one. This political "pendulum swing" can derail promising drugs, showing that regulatory risk is not static but subject to unpredictable political change.

Internal power shifts at the FDA, such as Vinay Prasad's rising influence, create a chilling effect on review teams. Even without direct orders, reviewers feel less emboldened to be flexible when leadership's public stance favors greater rigor. This 'tone from leadership' can shift regulatory outcomes more than explicit policy changes.

FDA CBER Director Vinay Prasad is reportedly overriding staff recommendations not just in his own center (vaccines), but also in CEDAR (drugs), as seen in the Disc Medicine case. This consolidation of decision-making power in one individual is making FDA approvals far more unpredictable for drug developers.

The replacement of CEDAR Director Richard Pazder with Tracy Beth Hoeg, who is viewed as an ideologue lacking regulatory experience, signals a shift toward politically driven decisions at the FDA. This move creates significant uncertainty and raises concerns that ideology, not science, will influence drug approvals.

Recent events, like Moderna's rescinded 'refusal to file' letter, reveal that alignment with FDA staff on trial design is no guarantee. Senior leaders, notably Vinay Prasad, are reportedly overturning prior agreements, creating extreme uncertainty and making it impossible for companies to trust the regulatory guidance they receive.

FDA Commissioner Macari is facing intense criticism, including from conservative media. This pressure may be compelling the agency to greenlight approvals, particularly for orphan drugs, to appease powerful patient advocacy groups and improve the agency's political standing ahead of potential leadership changes.

The focus on Vinay Prasad's personality misses the larger institutional crisis at the FDA: a shift from large, team-based scientific reviews to centralized, politically-influenced decisions made by a few individuals. This 'picking winners and losers' approach undermines the agency's scientific integrity, regardless of who is in charge.